The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Association of the HLA–DRB1 gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis
Open accessAbstract
Objective: To examine the role of the variants of the PTPN22 and HLA–DRB1 genes as predictors of mortality in inflammatory polyarthritis (IP) and rheumatoid arthritis (RA). Methods: Patients were recruited from a primary care–based inception cohort of patients with IP and were followed up prospectively. For patients who died, the cause and date of death was obtained. Cox proportional hazards regression models were used to assess the association of the HLA–DRB1 (including the shared epitope [SE]) and PTPN22 genes with the risk of death from all causes and from cardiovascular disease (CVD) and to assess the interactions between SE, smoking, and anti–cyclic citrullinated peptide (anti‐CCP) status, adjusted by age at symptom onset and sex. Results: DNA samples were available from 1,022 IP patients. During followup, 751 of them (74%) satisfied the American College of Rheumatology 1987 criteria for RA, and 242 of them (24%) died. Carriage of 2 copies of SE alleles predicted death from all causes (hazard ratio [HR] 1.57 [95% confidence interval (95% CI) 1.1–2.2]) and from CVD (HR 1.68 [95% CI 1.1–2.7]). This effect was most marked for individuals with the HLA–DRB1*01/*04 combination. An interaction of smoking, SE alleles, and anti‐CCP antibodies was observed and was associated with the greatest risk of death from CVD (HR 7.81 [95% CI 2.6–23.2]). No association of the PTPN22 gene with mortality was detected. Conclusion: SE alleles, particularly compound heterozygotes, are associated with death from all causes and from CVD, independently of autoantibody status. However, the combination of SE, smoking, and anti‐CCP antibodies is associated with a high risk of premature death in patients with IP and RA, which raises the possibility of a targeted strategy to prevent CVD in these patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
Ridker, P. M., Cushman, M., Stampfer, M. J., Tracy, R. P., & Hennekens, C. H. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704033361401 · Cited by 5,504
Cited by
Peters, M. J. L., Symmons, D. P. M., McCarey, D., Dijkmans, B. A. C., Nicola, P., Kvien, T. K., McInnes, I. B., Haentzschel, H., Gonzalez-Gay, M. A., Provan, S., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.113696 · Cited by 1,325
Self-citationKlareskog, L., Catrina, A. I., & Paget, S. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60008-8 · Cited by 787
Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE
Symmons, D. P. M., & Gabriel, S. E. (2011) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2011.75 · Cited by 406
Self-citationKällberg, H., Ding, B., Padyukov, L., Bengtsson, C., Rönnelid, J., Klareskog, L., & Alfredsson, L. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.120899 · Cited by 401
Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives
Kitas, G. D., & Gabriel, S. E. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.142133 · Cited by 321
Atherosclerosis in rheumatoid arthritis: is it all about inflammation?
Skeoch, S., & Bruce, I. N. (2015) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.40 · Cited by 281
Subclinical Atherosclerosis in Rheumatoid Arthritis and Systemic Lupus Erythematosus
Salmon, J. E., & Roman, M. J. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.06.010 · Cited by 256
Provan, S., Angel, K., Semb, A. G., Atar, D., & Kvien, T. K. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.127704 · Cited by 50
Metadata
- Authors
- Farragher, T. M., Goodson, N. J., Naseem, H., Silman, A. J., Thomson, W., Symmons, D., & Barton, A.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2008-01-31
- Volume
- 58
- Issue
- 2
- Pages
- 359-369
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2113834933
- Cited by
- 181
- References
- 1
- FWCI
- 11.72
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.